9月4日，康方生物盘中上涨5.73%，报96.0港元，成交额5081.05万港元。
消息面上，公司9月3日宣布依沃西单抗对比帕博利珠单抗（K药）一线治疗PD-L1阳性非小细胞肺癌的III期研究HARMONi-2，在期中分析中达到总生存期（OS）关键次要终点，取得具有统计学显著性和临床获益的阳性结果，该研究共入组398例受试者。此前依沃西已在胆道癌III期HARMONi-GI1中头对头击败度伐利尤取得OS阳性结果，第三个肺癌适应症一线治疗鳞状NSCLC亦于8月获批上市。国信证券维持"优于大市"评级，指双抗放量加速，商业化效率持续提升。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.